GynTect

quickly get a reliabe diagnosis

Innovation for laboratories

GynTect.

GynTect.

reliable diagnosis

Questions regarding GynTect?

Get the answers!

Questions regarding GynTect?

Get the answers!

Welcome to Epitype GmbH in Jena

Since 2012, we have been conducting research – initially as oncgnostics GmbH and since 2025 as Epitype GmbH – on the molecular biological diagnostics of cancer. Our cancer tests are used in cancer screening and diagnosis.

Our first product, GynTect®, was developed with the aim of improving cervical cancer screening. The molecular biological test for cervical cancer has been on the market since 2015 and is an example of the technology in which we, as a biotech company, specialize: Highly informative biomarkers, patented by us, form the heart of the company. Experienced scientists work together on innovative cancer diagnostics for the future.

Epitype GmbH – Molecular Biotechnology from Jena

Located in the heart of Jena, we, Epitype GmbH, leverage the advantages of this university city to work as a young research team on innovations in the field of molecular diagnostics. Experienced scientists can thus work together to create the foundations for improved cervical cancer diagnostics in the future.

Products

The GynTect® and ScreenYu Gyn® tests provide fast and reliable support in the early detection of cervical cancer.

More information

About us

The management and highly motivated team of Epitype GmbH consist of industry-experienced and ambitious scientists.

More information

Contact us

Partner oncgnostics GmbH

If you have any questions about our products and our research, we look forward to hearing from you.

More information

GynTect® could be a very good addition to tests for infections with human papillomaviruses. The data indicate that the test could identify those among the many HPV-infected women who require a precise clarification of a precancerous lesion.

Epitype has identified and clinically validated patent-protected biomarkers. These can be used for a wide variety of cancer diagnostics. This offers strategic partners from the pharmaceutical and diagnostics industries access to innovative and reliable testing methods in a growth market.

News and current events

Bachelor thesis in biotechnology companies: An experience reportoncgnostics GmbH

Worldwide unique test for cervical cancer as a gamechanger for the healthcare system

Cancer is and remains one of the greatest health, medical and socio-political challenges of our time. This is also made clear by the World Health Organization's (WHO) forecast, which predicts a 77% increase in the number of cancers detected…
Read more
Biotechnologieunternehmen aus Jena stellt Insolvenzantrag: oncgnostics GmbH

Jena Biotechnology Company Files for Insolvency

Jena, Thuringia, March 31, 2025. Jena-based Oncgnostics GmbH has filed for insolvency. The Gera District Court has ordered and appointed lawyer Kai Dellit from the law firm hww hermann wienberg wilhelm as the provisional insolvency administrator.…
Read more
Bachelor thesis in biotechnology companies: An experience reportoncgnostics GmbH

Bachelor thesis in biotechnology companies: From research to diagnostics 

What can emerge from basic research? This question followed Lena Bernstein during her studies in Biochemistry and Molecular Biology at the University of Jena. To find answers, she chose to write her bachelor’s thesis at a biotechnology company.…
Read more

Individual projects in our company are co-financed by the European Union with ERDF and ESF funds and the Free State of Thuringia (Thuringian Ministry of Economics, Science and Digital Society).

We are an active member of GPeV – Society for Prevention (registered association), a network and cross-organizational implementation body for topics and projects related to health promotion and prevention.